Global Bacterial Conjunctivitis Drugs Market 2016-2020

  • ID: 3623661
  • Report
  • Region: Global
  • 57 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Akorn
  • Bayer
  • F. Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Bacterial Conjunctivitis Drugs

Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis. Antibiotics help in eradicating the microbes, resulting in faster clearance of the symptoms. Broad-spectrum antibiotics such as Besivance, Zymaxid, Maxitrol, and AzaSite, in the form of antibiotic pills, ointment, or eye drops help treat the infection. Fluoroquinolones, macrolides, aminoglycosides, and phenicols are among the different classes of antibiotics that are commonly prescribed to treat the condition.

The analysts forecast the global bacterial conjunctivitis drugs market to grow at a CAGR of 2.77% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global bacterial conjunctivitis drugs market for 2015-2020. To calculate the market size, it considers revenue generated from the sales of branded and generic drugs along with over-the-counter (OTC) drugs used to treat bacterial conjunctivitis.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Bacterial Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors:

- Akorn
- Alcon
- Allergan
- Bausch & Lomb

Other prominent vendors:

- Bayer
- Daiichi Sankyo
- F. Hoffmann-La Roche
- InSite Vision
- Merck
- Nicox
- Novartis
- Perrigo
- Pfizer
- Santen Pharmaceutical
- Shire
- Valeant Pharmaceuticals

Market drivers

- Rising awareness about infections
- For a full, detailed list, view the full report

Market challenges

- Patent expiry of drugs
- For a full, detailed list, view the full report

Market trends

- Patient assistance programs
- For a full, detailed list, view the full report

Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akorn
  • Bayer
  • F. Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Overview: Bacterial conjunctivitis
  • Conjunctivitis
  • Bacterial conjunctivitis
  • Signs and symptoms
  • Diagnosis
  • Management
  • Economic burden
PART 06: Pipeline analysis
  • FST-100
  • AzaSite Xtra (ISV-405)
PART 07: Antimicrobial resistance
  • Initiatives to improve innovation of antibiotics
PART 08: Legislation relating to antibiotic use in US

PART 09: Market landscape
  • Market overview
  • Market size and forecast
  • Bacterial conjunctivitis drugs market in US
  • Five forces analysis
PART 10: Market segmentation by drug class
  • Fluoroquinolones
  • Aminoglycosides
  • Macrolides
  • Other
PART 11: Geographical segmentation
  • Global bacterial conjunctivitis drugs market by geography 2015-2020
  • Bacterial conjunctivitis drugs market in Americas
  • Bacterial conjunctivitis drugs market in EMEA
  • Bacterial conjunctivitis drugs market in APAC
PART 12: Market drivers
  • Rising awareness about infection
  • Development of multidrug-resistant variants
  • Prevalence of bacterial conjunctivitis
PART 13: Impact of drivers

PART 14: Market challenges
  • Patent expiry of drugs
  • Contentment with existing therapies
  • Adverse effects and limited efficacy of drugs
  • Weak R&D of drugs
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Strategic alliances and M&A
  • Use of combination therapies
  • Patient assistance programs
PART 17: Vendor landscape
  • Competitive scenario
  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Types of conjunctivitis
Exhibit 03: Types of bacterial conjunctivitis
Exhibit 04: Signs and symptoms of bacterial conjunctivitis
Exhibit 05: Drugs used to treat conjunctivitis
Exhibit 06: Global bacterial conjunctivitis drugs market: Pipeline portfolio
Exhibit 07: Causes of antimicrobial resistance
Exhibit 08: Initiatives improving antibiotic innovation
Exhibit 09: Legislation relating to antibiotic use in US
Exhibit 10: Global bacterial conjunctivitis drugs market 2015-2020 ($ billions)
Exhibit 11: Snapshot of global bacterial conjunctivitis drugs market
Exhibit 12: Percentage share of bacterial conjunctivitis drugs market in US
Exhibit 13: Bacterial conjunctivitis drugs market in US 2015-2020 ($ millions)
Exhibit 14: Five forces analysis
Exhibit 15: Global bacterial conjunctivitis drugs market by drug class
Exhibit 16: Global bacterial conjunctivitis drugs market by geography 2015
Exhibit 17: Global bacterial conjunctivitis drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Bacterial conjunctivitis drugs market in Americas 2015-2020 ($ millions)
Exhibit 19: Bacterial conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 20: Bacterial conjunctivitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 21: Global bacterial conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 22: Key drivers
Exhibit 23: Impact of drivers
Exhibit 24: Key challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key trends
Exhibit 27: Akorn: YoY growth and revenues in ophthalmic segment 2011-2013 ($ millions)
Exhibit 28: Akorn: Key takeaways
Exhibit 29: Business segmentation by revenue 2014
Exhibit 30: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
Exhibit 31: Alcon: Key takeaways
Exhibit 32: Allergan: Key takeaways
Exhibit 33: Bausch & Lomb: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Akorn
  • Bayer
  • F. Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: – Global Bacterial Conjunctivitis Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Bacterial Conjunctivitis Drugs Market: Akorn, Alcon, Allergan and Bausch & Lomb.

Other Prominent Vendors in the market are: Bayer, Daiichi Sankyo, F. Hoffmann-La Roche, InSite Vision, Merck, Nicox, Novartis, Perrigo, Pfizer, Santen Pharmaceutical, Shire and Valeant Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The patient assistance programs for conjunctivitis are expected to boost the growth of the market during the forecast period. Vendors are providing co-pay assistance to patients who purchase medications for conjunctivitis. For instance, Bausch & Lomb provides patient assistance programs for patients who are not covered by any private or government insurances. It provides assistance programs for drugs such as Besivance, Alrex, and Zylet, which are used to treat ophthalmic indications. Since the drug suppliers provide the assistance programs, patients are inclined toward buying branded therapies.”

According to the report, the rising awareness about conjunctivitis has resulted in an understanding about how to prevent and control the infection. This has been possible because of numerous awareness programs.

Further, the report states that Patent expiries result in the entry of generics, leading to a decline in the sales of branded drugs. The generics are usually just as effective and safe as the original drugs and come with the added advantage of lower costs. This will result in a major decline in the overall revenue of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- Akorn
- Alcon
- Allergan and Bausch & Lomb
- Bayer
- Daiichi Sankyo
- F. Hoffmann-La Roche
- InSite Vision
- Merck
- Nicox
- Novartis
- Perrigo
- Pfizer
- Santen Pharmaceutical
- Shire
- Valeant Pharmaceuticals.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll